Which Is the Better iShares ETF for Small-Cap Value Investing, ISCV or IWN?

ISCV offers a much lower 0.06% expense ratio versus IWN’s 0.24% and a slightly higher 1.9% dividend yield versus 1.5%, while IWN still leads on 1-year return at 48.6% versus 37.5%. On a five-year basis, ISCV has a slightly smaller max drawdown (-25.34% vs. -26.71%) and lower growth of $1,000 ($1,420 vs. $1,397), but it is far smaller at $644.5 million AUM versus $13.4 billion for IWN, implying lower liquidity. The piece is a relative-value ETF comparison with limited direct market-moving impact.

Analysis

The real edge here is not the headline cost gap; it is the different implementation path for the same factor exposure. ISCV’s lower fee and slightly better drawdown profile make it a cleaner long-horizon vehicle, but its smaller asset base also means wider spreads and more market impact when value rotates abruptly. IWN’s larger wrapper should capture more of the fast-money factor flow when rates fall or cyclicals rip, even if the extra fee leaks more return over a multi-year hold.

The more interesting second-order issue is sector and constituent concentration. Both funds are effectively a bet on financials plus cyclical industrial/value names, so the trade is less “small-cap value” and more “rate-sensitive domestic cyclicals with idiosyncratic single-name risk.” The presence of MRNA in the smaller-cap value basket highlights that the index methodology can pull in turnaround names that are not classic economically-sensitive value; that makes the sleeve vulnerable to sentiment reversals in biotech-style binary stories even when the macro tape is supportive.

Near term, the main catalyst is the path of rates and the durability of the small-cap factor rally. If yields stall or re-accelerate, the lower-duration balance sheets and dividend support inside these portfolios should help relative performance, but a renewed risk-off tape would quickly expose liquidity in ISCV. Conversely, if market breadth continues to improve, IWN likely outperforms on flow and tradability, while ISCV quietly compounds better over 12-24 months. The consensus may be overvaluing the recent 1-year return gap and underweighting how much of that is just index composition and liquidity premium rather than sustainable alpha.

Key Decisions for Investors

• Long ISCV / short IWN as a 6-12 month relative-value trade: expect fee drag and concentration quality to matter more once the small-cap momentum burst cools; target modest upside with lower carry, but stop if small-cap breadth accelerates and bid-ask liquidity becomes the dominant driver.
• For tactical traders, use IWN for short-dated exposure into a continued rate-down or risk-on move: higher liquidity makes it the better vehicle for 1-4 week positioning, with cleaner exit risk if the factor reverses.
• If building a strategic allocation, prefer ISCV on a 12-24 month hold: the 18 bps annual fee difference compounds meaningfully, and the slightly lower drawdown profile should preserve more capital through a risk-off tape.
• Hedge small-cap value exposure with a short in a rate-sensitive financials proxy or bank ETF if yields are unstable: both funds are implicitly loaded to financials, so the hidden beta is to the shape of the yield curve more than to generic equity beta.
• Watch MRNA-specific headline risk inside ISCV as a tail event: if biotech sentiment weakens, the fund can suffer idiosyncratic slippage despite the diversified sleeve; avoid using ISCV for size-sensitive, intraday executions.